Provided by Tiger Fintech (Singapore) Pte. Ltd.

Travere Therapeutics, Inc.

21.15
+0.39001.88%
Post-market: 21.150.00000.00%16:20 EDT
Volume:2.33M
Turnover:48.90M
Market Cap:1.88B
PE:-5.19
High:21.71
Open:21.09
Low:20.15
Close:20.76
Loading ...
May 12, 2022

Major Issues Report

8-K - Current report
May 05, 2022

Major Issues Report

8-K - Current report
May 05, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Apr 20, 2022

Major Issues Report

8-K - Current report
Mar 21, 2022

Major Issues Report

8-K - Current report
Mar 11, 2022

Major Issues Report

8-K - Current report
Mar 09, 2022

[Supp]Public Prospectus

FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
Mar 09, 2022

[Supp]Public Prospectus

FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
Feb 24, 2022

Major Issues Report

8-K - Current report
Feb 24, 2022

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 14, 2022

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 14, 2022

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 14, 2022

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 14, 2022

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 14, 2022

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Feb 10, 2022

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 10, 2022

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Jan 10, 2022

Major Issues Report

8-K - Current report
Jan 06, 2022

Major Issues Report

8-K - Current report
Dec 22, 2021

Major Issues Report

8-K - Current report